Cardinal Health, Inc.

Cardinal Health, Inc. (CAH) Stock Analysis

$234.550

-0.586 (-0.25%)At close

Loading chart…
High
236.800
Open
236.020
VWAP
235.02
Vol
1.78M
Mkt Cap
24.26B
Low
233.720
Amount
418.15M
EV/EBITDA, TTM
12.71

Cardinal Health, Inc. is a global healthcare services and products company. The Company is engaged in providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and others. It also provides pharmaceuticals and medical products. Its segments include Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD). The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty pharmaceuticals and over-the-counter healthcare and consumer products in the United States, as well as owns a urology management services organization (MSO). Its GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. It connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination.

AI analysis of Cardinal Health, Inc. (CAH)

buy

Cardinal Health Inc is a good buy right now due to its strong projected earnings growth of 13-15% for fiscal 2027, with analysts targeting a price increase to between $260 and $280, compared to the current price of $234.55. Additionally, the stock has shown a year-to-date change of +14.01%, indicating positive momentum.

Analyst Ratings (16)

-3.99% downside
Hold
1 Buy
15 Hold
0 Sell
Current: 234.55
Low
209.00
Average
225.18
High
244.00

RBC Capital

2026-08-19

Price Target

$276

Outperform

TD Cowen

2026-08-13

Price Target

$280

Buy

JPMorgan

2026-08-13

Price Target

$260

Neutral

Barclays

2026-08-13

Price Target

$275

Overweight

Morgan Stanley

2026-08-12

Price Target

$265

Overweight

Valuation Metrics

The current forward P/E ratio for Cardinal Health, Inc. (CAH) is 18.94, compared to its 5-year average forward P/E of 14.06.

Forward P/E

Overvalued
5Y Average P/E
14.06
Current P/E
18.94
Overvalued
17.00
Undervalued
11.12

Forward EV/EBITDA

Overvalued
5Y Average EV/EBITDA
9.58
Current EV/EBITDA
12.71
Overvalued
11.79
Undervalued
7.37

Forward P/S

Strongly Overvalued
5Y Average P/S
0.12
Current P/S
0.19
Overvalued
0.16
Undervalued
0.09

Alphio AI Price Scenarios for CAH

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%CAH

$146.16

Scenario price

B

Base

Base · 50%CAH

$128.79

Scenario price

B

Bear

Bear · 25%CAH

$107.97

Scenario price

Whales holding CAH

I

Integral Health Asset Management, LLC

+ HoldingCAHREGN

+15.08%

3M Return

C

Crawford Investment Counsel, Inc.

+ HoldingCAH

+10.17%

3M Return

P

Pacer Advisors, Inc.

+ HoldingCAH

+6.96%

3M Return

K

Kepler Cheuvreux SA

+ HoldingCAH

+3.16%

3M Return

C

CWA Asset Management Group, LLC

+ HoldingCAH

+2.03%

3M Return

V

Voleon Capital Management LP

+ HoldingCAH

+1.75%

3M Return

Events Timeline

2026-08-12 (ET)

08:30:00

Keurig Dr Pepper Appoints Aaron Alt as Director

2026-08-11 (ET)

16:30:00

Major Averages Close Broadly Lower as Investors Await CPI Report

12:00:00

Major Averages Dip Slightly as Investors Await CPI Report

10:00:00

Cardinal Health and Others See Morning Gains

09:00:00

Stock Futures Modestly Higher as Investors Await CPI Report

News

CAH FAQ — answered by Alphio AI

Cardinal Health, Inc. is a global healthcare services and products company. The Company is engaged in providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and others. It also provides pharmaceuticals and medical products. Its segments include Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD). The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty pharmaceuticals and over-the-counter healthcare and consumer products in the United States, as well as owns a urology management services organization (MSO). Its GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. It connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination. It operates in the Healthcare sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).

Cardinal Health Inc is a good buy right now due to its strong projected earnings growth of 13-15% for fiscal 2027, with analysts targeting a price increase to between $260 and $280, compared to the current price of $234.55. Additionally, the stock has shown a year-to-date change of +14.01%, indicating positive momentum.

16 analysts cover CAH: 1 rate it Buy, 15 Hold and 0 Sell. The average price target is 225.18.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始